Table 3 Tumour response, progression-free survival, and overall survival
Total (n = 34) | Second line (n = 25) | Third line (n = 9) | P-valuea | |
|---|---|---|---|---|
Response | ||||
Complete response | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0.988 |
Partial response | 7 (20.6%) | 5 (20.0%) | 2 (22.2%) | |
Stable disease | 19 (55.9%) | 14 (56.0%) | 5 (55.6%) | |
Progressive disease | 8 (23.5%) | 6 (24.0%) | 2 (22.2%) | |
Objective response rate | 20.6% | 20.0% | 22.2% | |
Disease control rate | 76.5% | 76.0% | 77.8% | |
Progression-free survival | 4.1 months (95% CI, 2.8–5.7) | 4.4 months (95% CI, 2.9– 5.9) | 3.5 months (95% CI, 2.2–4.8) | 0.064 |
Overall survival | 7.8 months (95% CI, 5.9–12.2) | 7.8 months (95% CI, 5.4–10.2) | 6.8 months (95% CI, 5.6–8.0) | 0.796 |
